Guardant settles Illumina litigation, extends commercial partnership with three-year agreement

Guardant Health, Inc.

Guardant and Illumina agreed to dismiss with prejudice the March 2022 Delaware lawsuit, including all IP allegations.
New three-year collaboration covers sharing of specimen samples for cancer research and a long-term purchase/supply commitment.
The agreement extends the companies' longstanding commercial relationship; no financial terms disclosed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.